Search results
Showing 61 to 75 of 314 results for breast cancer
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
Around 400 people with advanced breast cancer are set to benefit from a new treatment
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at moderately increased...
of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at high risk Published...
of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased...
1 of 11 Taking tamoxifen to reduce the chance of developing breast cancer Decision aid for premenopausal women at high risk Published...
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections